Tango Therapeutics (TNGX) News Today $4.08 +0.23 (+5.97%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Tango Therapeutics, Inc. (NASDAQ:TNGX) Director Purchases $36,200.00 in StockNovember 19 at 5:07 AM | insidertrades.comTrv Gp Iv LLC Has $129.82 Million Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)Trv Gp Iv LLC lessened its holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) by 12.2% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 16,859,075 shares of the company's stock after selling 2,342,400 shares duriNovember 17, 2024 | marketbeat.comTango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Recommendation of "Buy" from AnalystsNovember 15, 2024 | americanbankingnews.comTango Therapeutics, Inc. (NASDAQ:TNGX) Receives Average Rating of "Buy" from AnalystsShares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) have earned an average rating of "Buy" from the eight research firms that are covering the company, Marketbeat.com reports. Eight research analysts have rated the stock with a buy rating. The average 12-month price target among broNovember 15, 2024 | marketbeat.comB. Riley Lifts Earnings Estimates for Tango TherapeuticsNovember 15, 2024 | americanbankingnews.comB. Riley Boosts Earnings Estimates for Tango TherapeuticsTango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Analysts at B. Riley upped their FY2024 earnings per share estimates for shares of Tango Therapeutics in a research report issued on Monday, November 11th. B. Riley analyst Y. Zhi now forecasts that the company will earn ($1.21) per share forNovember 14, 2024 | marketbeat.comB. Riley Has Lowered Expectations for Tango Therapeutics (NASDAQ:TNGX) Stock PriceNovember 13, 2024 | americanbankingnews.comWhat is Leerink Partnrs' Estimate for TNGX FY2024 Earnings?November 13, 2024 | americanbankingnews.comTango Therapeutics (NASDAQ:TNGX) Earns "Buy" Rating from HC WainwrightNovember 12, 2024 | americanbankingnews.comTango Therapeutics price target lowered to $8 from $16 at B. RileyNovember 11, 2024 | markets.businessinsider.comB. Riley Cuts Tango Therapeutics (NASDAQ:TNGX) Price Target to $8.00B. Riley dropped their target price on shares of Tango Therapeutics from $16.00 to $8.00 and set a "buy" rating for the company in a research report on Monday.November 11, 2024 | marketbeat.comFY2024 Earnings Forecast for TNGX Issued By Leerink PartnrsTango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Equities research analysts at Leerink Partnrs lifted their FY2024 EPS estimates for Tango Therapeutics in a research report issued to clients and investors on Wednesday, November 6th. Leerink Partnrs analyst A. Berens now expects that the comNovember 11, 2024 | marketbeat.comPositive Outlook for Tango Therapeutics: Promising TNG462 Data and Strategic FocusNovember 10, 2024 | markets.businessinsider.comPromising Developments and Strategic Shifts at Tango Therapeutics: A Buy Rating with a $13 Price TargetNovember 9, 2024 | markets.businessinsider.comHC Wainwright Reaffirms Buy Rating for Tango Therapeutics (NASDAQ:TNGX)HC Wainwright reissued a "buy" rating and issued a $13.00 price target on shares of Tango Therapeutics in a research note on Friday.November 8, 2024 | marketbeat.comTango Therapeutics, Inc. (NASDAQ:TNGX) Insider Sells $9,671,200.00 in StockNovember 8, 2024 | insidertrades.comWedbush Forecasts Reduced Earnings for Tango TherapeuticsTango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Investment analysts at Wedbush lowered their FY2024 EPS estimates for Tango Therapeutics in a research note issued on Wednesday, November 6th. Wedbush analyst R. Driscoll now forecasts that the company will earn ($1.16) per share for the yearNovember 8, 2024 | marketbeat.comTango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business HighlightsNovember 7, 2024 | finance.yahoo.comTango Therapeutics price target lowered to $8 from $18 at GuggenheimNovember 7, 2024 | markets.businessinsider.comTango Therapeutics Advances Cancer Treatment PipelineNovember 7, 2024 | markets.businessinsider.comTango Therapeutics (NASDAQ:TNGX) Price Target Lowered to $8.00 at GuggenheimGuggenheim cut their price objective on Tango Therapeutics from $18.00 to $8.00 and set a "buy" rating on the stock in a report on Thursday.November 7, 2024 | marketbeat.comTango Therapeutics announces update on PRMT5 programNovember 7, 2024 | markets.businessinsider.comBarclays Keeps Their Buy Rating on Tango Therapeutics (TNGX)November 7, 2024 | markets.businessinsider.comTango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development ProgramNovember 7, 2024 | finance.yahoo.comTango Therapeutics (NASDAQ:TNGX) Hits New 1-Year Low - Here's What HappenedTango Therapeutics (NASDAQ:TNGX) Sets New 52-Week Low - Time to Sell?November 4, 2024 | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth PlansOctober 29, 2024 | finance.yahoo.comTango Therapeutics (NASDAQ:TNGX) Reaches New 12-Month Low Following Insider SellingTango Therapeutics (NASDAQ:TNGX) Hits New 1-Year Low on Insider SellingOctober 29, 2024 | marketbeat.comInsider Selling: Tango Therapeutics, Inc. (NASDAQ:TNGX) Insider Sells 633,000 Shares of StockOctober 29, 2024 | insidertrades.comTango Therapeutics (NASDAQ:TNGX) Sees Unusually-High Trading Volume - Here's WhyTango Therapeutics (NASDAQ:TNGX) Sees Strong Trading Volume - Time to Buy?October 28, 2024 | marketbeat.comTango Therapeutics, Inc. (NASDAQ:TNGX) Sees Significant Decrease in Short InterestTango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) was the recipient of a large decline in short interest in the month of October. As of October 15th, there was short interest totalling 8,900,000 shares, a decline of 17.7% from the September 30th total of 10,810,000 shares. Approximately 15.4% of the company's shares are sold short. Based on an average daily trading volume, of 916,600 shares, the days-to-cover ratio is presently 9.7 days.October 28, 2024 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Tango Therapeutics (NASDAQ:TNGX)HC Wainwright reaffirmed a "buy" rating and set a $13.00 price target on shares of Tango Therapeutics in a report on Monday.October 28, 2024 | marketbeat.comPiper Sandler Reaffirms Their Buy Rating on Tango Therapeutics (TNGX)October 26, 2024 | markets.businessinsider.comTango Therapeutics (NASDAQ:TNGX) Trading Up 8.7% - Still a Buy?Tango Therapeutics (NASDAQ:TNGX) Stock Price Up 8.7% - What's Next?October 25, 2024 | marketbeat.comInsider Selling: Tango Therapeutics, Inc. (NASDAQ:TNGX) Insider Sells 625,000 Shares of StockOctober 24, 2024 | insidertrades.comTango Therapeutics (NASDAQ:TNGX) Reaches New 1-Year Low - What's Next?Tango Therapeutics (NASDAQ:TNGX) Reaches New 12-Month Low - What's Next?October 23, 2024 | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Trading Down 7.6% - Time to Sell?Tango Therapeutics (NASDAQ:TNGX) Stock Price Down 7.6% - Time to Sell?October 22, 2024 | marketbeat.comTango Therapeutics, Inc. (NASDAQ:TNGX) Receives Average Recommendation of "Buy" from AnalystsShares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) have been assigned a consensus rating of "Buy" from the eight ratings firms that are presently covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy rating and one has assigned a strong bOctober 21, 2024 | marketbeat.comTango Therapeutics: A Buy Rating on PRMT5 Inhibitor Prospects and Upcoming Clinical DataOctober 16, 2024 | markets.businessinsider.comTango Therapeutics (NASDAQ:TNGX) Sees Unusually-High Trading Volume - Here's What HappenedTango Therapeutics (NASDAQ:TNGX) Sees Unusually-High Trading Volume - Here's What HappenedOctober 14, 2024 | marketbeat.comDimensional Fund Advisors LP Buys 100,257 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX)Dimensional Fund Advisors LP raised its position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) by 42.5% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 335,913 shares of the company's stock aftOctober 11, 2024 | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Shares Down 5.8% - Here's WhyTango Therapeutics (NASDAQ:TNGX) Trading Down 5.8% - Time to Sell?October 10, 2024 | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.com447,107 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Bought by Point72 Asset Management L.P.Point72 Asset Management L.P. acquired a new position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 447,107 shares of the company's stockOctober 3, 2024 | marketbeat.comTango Therapeutics, Inc. (NASDAQ:TNGX) Shares Sold by Ensign Peak Advisors IncEnsign Peak Advisors Inc cut its stake in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) by 46.3% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 271,822 shares of the company's stock after sSeptember 28, 2024 | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Shares Down 3% Tango Therapeutics (NASDAQ:TNGX) Stock Price Down 3%September 23, 2024 | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Stock Price Up 3%Tango Therapeutics (NASDAQ:TNGX) Trading 3% HigherSeptember 18, 2024 | marketbeat.comTango Therapeutics, Inc. (NASDAQ:TNGX) Major Shareholder Rock Ventures Iv L.P. Third Sells 67,400 SharesSeptember 18, 2024 | insidertrades.comTango Therapeutics (NASDAQ:TNGX) Shares Down 12.4% Tango Therapeutics (NASDAQ:TNGX) Stock Price Down 12.4%September 16, 2024 | marketbeat.comTango Therapeutics: A Buy Rating Amidst Competitive Advantages and Promising Market ValuationSeptember 11, 2024 | markets.businessinsider.comTango Therapeutics (NASDAQ:TNGX) Trading Up 8.8%Tango Therapeutics (NASDAQ:TNGX) Stock Price Up 8.8%September 11, 2024 | marketbeat.com Get Tango Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNGX and its competitors with MarketBeat's FREE daily newsletter. Email Address Urgent: This election is rigged (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soon Click here to watch it now. TNGX Media Mentions By Week TNGX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TNGX News Sentiment▼0.740.46▲Average Medical News Sentiment TNGX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TNGX Articles This Week▼113▲TNGX Articles Average Week Get Tango Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNGX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OUST News Today DCGO News Today EOSE News Today PRCH News Today QSI News Today ORGN News Today LTCH News Today MNTS News Today CMPO News Today XNCR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TNGX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tango Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tango Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
